

REMARKS/ARGUMENTS

Claims 6-7, 14, and 22 are canceled.

Claims 30-32 are new.

Support for each new and amended claim is found throughout the specification and at the originally filed claims. Support for Claims 30 and 31, and amended Claims 1 and 8, is found, for example, at page 11, Table 1, page 11, Table 2, page 13, Table 3, and at page 7, lines 35-38.

Upon entry of the amendment, Claims 1-5, 8-13, 15-21, and 23-32 will be active.

No new matter has been added.

Applicants respectfully traverse the anticipation rejection of Claims 1-13, 16-21 and 24-25 as being unpatentable over Julian. The rejection of Claims 6-7 is obviated by cancellation of Claims 6-7. The fluid carrier of the suspension of Julian is required to be a pharmacologically acceptable fluid carrier (see column 2, lines 3-4). Claims 1 and 8, and the claims depending therefrom, require that the organic suspension medium contain at least one of dimethylsulfoxide, toluene, tetrahydrofuran, cyclohexanone, and dimethylformamide. An organic suspension medium containing at least one of dimethylsulfoxide, toluene, tetrahydrofuran, cyclohexanone, and dimethylformamide would not be a pharmacologically acceptable fluid carrier, and thus, Julian cannot anticipate the claims. Withdrawal of the rejection is respectfully requested.

The anticipation rejection of Claims 1-6, 8-11, 13, 16-19, 21, 24 and 25 as being unpatentable over Keller is respectfully traversed. The rejection of Claim 6 is obviated by cancellation of Claim 6. Keller requires a film-forming binder (see, for example, the Abstract, and column 2, lines 45-47, of Keller) for the composition, which is absent from present Claim 8, or a suspension medium with a binder dissolved therein, which is absent

from Claim 1. The present Claims 1 and 8, and the claims depending therefrom, are not anticipated by Keller. Withdrawal of the anticipation rejection is respectfully requested.

The obviousness rejection of Claims 15 and 23 as being unpatentable over Keller in view of Tully is respectfully traversed. As discussed above, Keller, in requiring a film forming binder, does not describe or suggest the inventive embodiments of the present claims, and in fact, "teaches away" from them. The disclosure of Tully does not remedy the deficiency of Keller. Withdrawal of the rejection is requested.

Applicants submit the application is now in condition for allowance. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Charles J. Andres, Ph.D.  
Attorney of Record  
Registration No. 57,537

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)